Gyre Therapeutics financials
$7.32−2.27%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $116.6M | $105.8M | $113.5M |
| Gross profit | $111.2M | $101.9M | $108.8M |
| Gross margin | 95.4% | 96.3% | 95.9% |
| Operating income | $11.5M | $16.2M | -$63.9M |
| Net income | $5.0M | $12.1M | -$92.9M |
| Net margin | 4.3% | 11.4% | −81.9% |
| Diluted EPS | $0.02 | $0.05 | $-1.41 |
| EBITDA | $14.0M | $17.8M | -$62.8M |
| Operating cash flow | $1.0M | -$3.6M | $25.9M |
| Free cash flow | -$180.0K | -$6.0M | $17.4M |
| Diluted shares | 103.2M | 102.3M | 65.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $49.2M | $11.8M | $33.5M |
| Short-term investments | $43.4M | $14.9M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $219.8M | $125.4M | $116.5M |
| Total liabilities | $31.4M | $27.0M | $38.1M |
| Shareholders' equity | $59.5M | $98.4M | $13.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology